Business
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Adm
About this update from Zenas Biopharma, Inc.
[{"type":"image","alt":"Zenas BioPharma","displaySize":"","headline":null,"caption":"Zenas BioPharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bjxJdSV_PbdPJT7f1Gm1fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NA--/https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1","width":300,"height":117},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/bjxJdSV_PbdPJT7f1Gm1fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NA--/https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1","width":300,"height":117}},"lazy":false},{"type":"text","content":"- BLA submission based on positive results from Phase 3 INDIGO trial -","length":70,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD). IgG4-RD is a debilitating chronic fibro-inflammatory disease affecting multiple organ systems, often resulting in irreversible tissue damage and organ failure. Obexelimab, an investigational therapy, is a bifunctional monoclonal antibody designed to bind both CD19 and FcgRIIb to inhibit B cell function.","length":808,"tagName":"p"},{"type":"text","content":"“Our obexelimab BLA submission brings us one step closer to our goal of delivering this meaningful treatment option to patients living with IgG4-RD. Based on the significant clinical activity and the favorable safety and tolerability profile observed in the INDIGO study, we believe obexelimab may have an important role as a first line therapy in the long-term management of IgG4-RD,” said Lisa von Moltke, M.D., Head of Research & Development & Chief Medical Officer of Zenas. “This regulatory submission marks a significant milestone for Zenas, and we would like to thank the patients, healthcare professionals and the Zenas team w...